| dc.contributor.advisor | 張元晨 | zh_TW |
| dc.contributor.advisor | Chang, Yuan chen | en_US |
| dc.contributor.author (Authors) | 丁秀文 | zh_TW |
| dc.contributor.author (Authors) | Ting, Hsiu Wen | en_US |
| dc.creator (作者) | 丁秀文 | zh_TW |
| dc.creator (作者) | Ting, Hsiu Wen | en_US |
| dc.date (日期) | 2007 | en_US |
| dc.date.accessioned | 14-Sep-2009 09:03:07 (UTC+8) | - |
| dc.date.available | 14-Sep-2009 09:03:07 (UTC+8) | - |
| dc.date.issued (上傳時間) | 14-Sep-2009 09:03:07 (UTC+8) | - |
| dc.identifier (Other Identifiers) | G0095357022 | en_US |
| dc.identifier.uri (URI) | https://nccur.lib.nccu.edu.tw/handle/140.119/31008 | - |
| dc.description (描述) | 碩士 | zh_TW |
| dc.description (描述) | 國立政治大學 | zh_TW |
| dc.description (描述) | 財務管理研究所 | zh_TW |
| dc.description (描述) | 95357022 | zh_TW |
| dc.description (描述) | 96 | zh_TW |
| dc.description.abstract (摘要) | 本文以事件研究法，討論美國食品暨藥物管理局在核准新藥上市的宣告效果。結果顯示在宣告日當天，各藥廠的異常報酬沒有顯著改變，但在宣告日的前五十天交易日可以觀察到顯著的累計異常報酬，根據美國食品暨藥物管理局的審核新藥流程以及學術性期刊對於新藥的臨床實驗數據探討，亦或是新聞對於新藥療效的提前揭露，推測皆會影響事件日之前的股價反應。進一步根據會計資料的觀察，新藥的核准上市，對於藥廠的營收雖沒有顯著改變，仍可以看出有增加的趨勢。最後，諸多新聞指出分析師對於新藥的審核過程中可以取得此藥物是否會通過美國食品暨藥物管理局的內線消息，結果顯示約有41％的分析師可以準確預測藥物是否可以通過，或許跟製藥業不同於其他產業的流程導致內線消息流出有關。 | zh_TW |
| dc.description.abstract (摘要) | In this paper, we use event-study to estimate the stock price changes of Food and Drug Administration (FDA) decisions on new products for pharmaceutical companies. We find that FDA decisions have insignificant effects in all countries on the drug approval date. The insignificant price changes accompanying FDA announcements approval suggest that drug results have leaked to the market. It is quite possible that the results of advisory are open to public and advisory committee are held before FDA approval, advisory committee can be viewed as important news source of drug approval. After the drug approved by the FDA, the new drugs may bring additional income to the companies. Although the accounting data are insignificant at five percent significant level, we still can peek that the companies with new approval drug have their EPS increase. Besides, 41% of analyst rates the performance of next quarter better than actual EPS at that time. The reason can be the access of undisclosed information about successful approval of new drugs. | en_US |
| dc.description.tableofcontents | Contents I.Introduction…………………………………………………………… 1 II.Literature Review…………………………………………………… 4 A. Characteristics of Bio-Pharmaceutical industry…4 B. FDA approve drug………………………………………………7 C. Drug news release before FDA approval date… 11 D. Analysts and insider-trading in Bio-Pharmaceutical industry…………………………………………………14 III.Data and Methodology……………………………………… 17 A .Data………………………………………………………… 17 B. Event-study for stock returns……………………… 18 C. Analysts’ Earnings Forecasts……………………… 20 IV.Results…………………………………………………………………… 22 V.Conclusions……………………………………………………………… 28 VI.References……………………………………………………………… 30 | zh_TW |
| dc.language.iso | en_US | - |
| dc.source.uri (資料來源) | http://thesis.lib.nccu.edu.tw/record/#G0095357022 | en_US |
| dc.subject (關鍵詞) | 美國食品暨藥物管理局 | zh_TW |
| dc.subject (關鍵詞) | 藥物 | zh_TW |
| dc.subject (關鍵詞) | 宣告效果 | zh_TW |
| dc.title (題名) | 美國食品暨藥物管理局藥物核准的宣告效果 | zh_TW |
| dc.title (題名) | Announcement Effect of Drug Approvals by FDA | en_US |
| dc.type (資料類型) | thesis | en |
| dc.relation.reference (參考文獻) | Abrams S., 1994, The Publication of Clinical Facts: A Natural-Science View, International Journal of Psycho-Analysis, 75, 1201-1210 | zh_TW |
| dc.relation.reference (參考文獻) | Acronym Required (http://www.acronymrequired.com/), 2005, Hedging Their Bets: Doctors, Pharmas and Investors | zh_TW |
| dc.relation.reference (參考文獻) | Adams C, Brantner V., 2006, Estimating the cost of new drug development: is it really 802 million dollars? Health Affairs, 25(2), 420–8 | zh_TW |
| dc.relation.reference (參考文獻) | Anand, Geeta and Smith, Randall, 2002, Trial Heat: Biotech Analysts Strive to Peek Inside Clinical Tests of Drugs-One Impersonated a Patient, One a Doctor; Firms Pay Physicians as Consultants- "Creativity Knows No Bounds`, The Wall Street Journal | zh_TW |
| dc.relation.reference (參考文獻) | Arnst, Catherine, 2002, How Drug News Leaks to Investors, Business Week, 3781, 32-33 | zh_TW |
| dc.relation.reference (參考文獻) | Baird, P., 2008, Clinical Trials and Industry, Science, 297, 2211 | zh_TW |
| dc.relation.reference (參考文獻) | Barnett, Antony, 2003, Revealed: how drug firms `hoodwink` medical journals, from website: guardian.co.uk︱The Observer | zh_TW |
| dc.relation.reference (參考文獻) | Bosch, Jean-Claude and Lee Insup, 1994, Wealth effects of Food and Drug Administration (FDA) Decisions, Managerial and Decision Economics, 15(6), 589-599 | zh_TW |
| dc.relation.reference (參考文獻) | Brown, S.J. and Warner, J.B., Using Daily Stock Returns: the Case of Event Studies, Journal of Financial Economics, 14, 3-31 | zh_TW |
| dc.relation.reference (參考文獻) | Church, Robert F., 2008, Pharmaceutical and Biotechnology Update, Pharmaceutical and Biotechnology Update, 1-3 | zh_TW |
| dc.relation.reference (參考文獻) | Danzon, Patricia M., Epstein, Andrew and Nicholson, Sean, 2004, Mergers and Acquisitions in the Pharmaceutical and Biotech Industries, The Wharton School of University of Pennsylvania | zh_TW |
| dc.relation.reference (參考文獻) | De Bondt, W. F. M. and Forbes, W. P., 1999, Herding in Analyst Earnings Forecasts: Evidence from the United Kingdom, European Financial Management 5, 143-163 | zh_TW |
| dc.relation.reference (參考文獻) | DiMasi J, Hansen R and Grabowski H, 2003, The price of innovation: new estimates of drug development costs, Journal of Health Economics, 22(2), 151–85. | zh_TW |
| dc.relation.reference (參考文獻) | Ferguson, James R., 1997, Biomedical Research and Insider Trading, The New England Journal of Medicine, 337, 631-634 | zh_TW |
| dc.relation.reference (參考文獻) | Frank, Richard G., 2003, New estimates of drug development costs, Journal of Health Economics, 22(2), 325-330 | zh_TW |
| dc.relation.reference (參考文獻) | Gad, Shayne Cox, 2005, Drug Discovery Handbook, Wiley-Interscience | zh_TW |
| dc.relation.reference (參考文獻) | Hadzovic, 1997, Pharmacy and the great contribution of Arab-Islamic science to its development, Medicines Archive, 51 (1-2), 47-50 | zh_TW |
| dc.relation.reference (參考文獻) | Huberman, Gur and T. Regev, 2001, Contagious Speculation and a Cure for Cancer: A non-event made stock prices soar, Journal of Finance, 56, 387-396 | zh_TW |
| dc.relation.reference (參考文獻) | Kraljevic, Sandra, Stambrook, Peter J. and Pavelic, Kresimir, 2004, Accelerating drug discovery, EMBO Reports, 5(9), 837-842 | zh_TW |
| dc.relation.reference (參考文獻) | Lenzer, Jeanne, 2005, What Can We Learn from Medical Whistleblowers? PLoS Medicine, 2(7), 583-586 | zh_TW |
| dc.relation.reference (參考文獻) | Liu, Qiao, 2006, How Good is Good News? Technology Depth, Book-to-Market Ratios, and Innovative Events, Journal of Accounting Auditing and Finance, 21 (3), 293-321 | zh_TW |
| dc.relation.reference (參考文獻) | Loomis, Carol J, 2008, Buffett’s biggest bets, Fortune | zh_TW |
| dc.relation.reference (參考文獻) | McGuire, John L., Hasskarl, Horst, Bode, Gerd, Klingmann, Ingrid and Zahn, Manuel, 2007, Pharmaceuticals: General Survey, Ullmann`s Encyclopedia of Chemical Technology | zh_TW |
| dc.relation.reference (參考文獻) | Moynihan R., 2008, Who pays for the pizza? Redefining the relationships between doctors and drug companies, British Medical Journal, 326(7400), 1193–1196 | zh_TW |
| dc.relation.reference (參考文獻) | Pollack, Andrew, 2002, ImClone Stock Sales Disclosed, The New York Times | zh_TW |
| dc.relation.reference (參考文獻) | Skolnick AA., 1998, SEC Going After Insider Trading Based on Medical Research Results, JAMA, 280(1), 10-11 | zh_TW |
| dc.relation.reference (參考文獻) | Stewart, James B., 2007, Investors Should Heed Warren Buffett`s Free Advice, Smart money | zh_TW |
| dc.relation.reference (參考文獻) | Stout, Hilary and Newman, Anne, 19 June 1991, FDA looks to stop leaks on drug stock, The Wall Street Journal | zh_TW |
| dc.relation.reference (參考文獻) | Timmerman, Luke and Heath, David, 2005, Drug researchers leak secrets to Wall St., The Seattle Times | zh_TW |
| dc.relation.reference (參考文獻) | Tufts Center for the Study of Drug Development | zh_TW |
| dc.relation.reference (參考文獻) | Unknown, 2003, Rising Nicely, Economist, 367(8327), 55-56 | zh_TW |
| dc.relation.reference (參考文獻) | Unknown, Drug Discovery & Development, 2005, industry trends | zh_TW |
| dc.relation.reference (參考文獻) | Wold, Kirsten, Schneider, Chad, Shields, Brandon and Kerwin, Ricky, 2002, Prescription Drug Market, Economics 333 | zh_TW |
